Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
  Top » Catalog » Books » Medicine » Cancer » Breast Cancer: Causes, Diagnosis and Treatment Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Time-Delay Systems: Concepts, Design and Stability Analysis
Shopping Cart more
0 items
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Immuno-Conjugates: New Prospects on Old Principles, pp. 189-197
Tell A Friend
Tell someone you know about this product.
Immuno-Conjugates: New Prospects on Old Principles, pp. 189-197 $100.00
Authors:  M.F. Barginear, D.R. Budman, The Tisch Cancer Insitute, The Mount Sinai School of Medicine, New York, NY, and others
Paul Ehrlich received the 1908 Nobel Prize in Medicine for his work in
Immunology [1]. He stated “The immune substances … in the manner of
magic bullets, seek out the enemy.” As such, he predicted the emergence of
targeted agents which have lessened effects on host tissue. However,
serotherapy was limited by the lack of appropriate targets, the inability to
make discrete antibodies with high specificity in large quantities, and the
reproducibility of the characteristics of the poly-antisera. In the late 1970’s,
George Köhler and César Milstein fundamentally changed Immunology by
developing the technology of hybridomas, the production of a desired
specific antibody in large amounts [2]. These investigators showed that
antibody-producing cells, of any specificity, could be fused with a myeloma
cell line and create an unlimited amount of monoclonal antibodies (mAb)
carrying that specificity [3]. This has led researchers, clinicians, and especially
biotechnology companies to focus on new diagnostic and therapeutic agents.
Oncology has been a major area of focus for mAb-based diagnostic and
therapeutic agents, primarily because of the overexpression of numerous
antigens on cancer cells compared with normal, non-cancerous cells and
tissues. As a single agent, trastuzumab (Herceptin®, Genentech) has
remarkable activity in Her2/neu over expressing breast cancers both in the
adjuvant and in the metastatic settings [4]. However, the majority of patients
with metastatic HER2 overexpressing breast cancer who initially respond to
trastuzumab develop resistance within one year of initiation of treatment, and
in the adjuvant setting, patients may still progress despite trastuzumab-based
therapy [5-8]. In analogous manner, Rituximab (Rituxan®, Genentech) has
been a major clinical advance in B-cell lymphomas [9]. Besides efficacy, the
off target effects of these agents are limited which adds to their attractiveness. 

Available Options:
This Item Is Currently Unavailable.
Special Focus Titles
01.Chaliapin and the Jews: The Question of Chaliapin's Purported Antisemitism
02.The Humanities: Past, Present and Future
03.The Poles: Myths and Reality
04.Child-Rearing: Practices, Attitudes and Cultural Differences
05."A Home Away from Home": A Community of International and South African University Students
06.Palliative Care: Oncology Experience from Hong Kong
07.The Enigma of Autism: Genius, Disorder or Just Different?
08.The Collector Mentality: Modernization of the Hunter-Gatherer
09.Face Processing: Systems, Disorders and Cultural Differences
10.Occurrences, Structure, Biosynthesis, and Health Benefits Based on Their Evidences of Medicinal Phytochemicals in Vegetables and Fruits. Volume 8
11.Crystal Growth: Concepts, Mechanisms and Applications
12.The Economic, Social and Political Impact of Mining on Akyem Abuakwa from the Pre-Colonial Era up to 1943

Nova Science Publishers
© Copyright 2004 - 2017

Immuno-Conjugates: New Prospects on Old Principles, pp. 189-197